Aspirin Resistance: Significance, Detection and Clinical Management of This Real Phenomenon Webcast May 10 th, 2004 Sponsored by.

Slides:



Advertisements
Similar presentations
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk.
Advertisements

Update on Anti-platelets Gabriel A. Vidal, MD Vascular Neurology Ochsner Medical Center October 14 th, 2009.
P H Y S I C I A N S ’ A C A D E M Y F O R C A R D I O V A S C U L A R E D U C A T I O N Insights from clinical trials: The unassailable case for LDL-c.
North of Tyne anti-platelet guidelines: use in primary care Jane S Skinner Consultant Community Cardiologist.
Presenter Disclosure Information Paul M Ridker, MD, FACC Dr Ridker is listed as a co-inventor on patents held by the Brigham and Women’s Hospital that.
Stroke Issues & prevention. Agenda  Impact of Stroke –Definitions –Epidemiology –Risk factors  Management of Stroke –Acute management –Primary & Secondary.
Jonathan A. Edlow, MD, FACEP Transient Ischemic Attack Patient Update: The Optimal Management of Emergency Department Patients With Suspected Cerebral.
Effect of Aspirin Dose on Platelet Reactivity in Diabetic Patients Effect of Aspirin Dose on Platelet Reactivity in Diabetic Patients Paul A. Gurbel, MD.
Women's Health Study: Low-Dose Aspirin in Primary Prevention Presented at American College of Cardiology Scientific Sessions 2005 Presented by Dr. Dr.
Leadership. Knowledge. Community. Antiplatelet Therapy for Secondary Prevention Beyond One Year Following ACS or PCI Working Group: Anil Gupta MD, FRCPC,
1 Therapies Not Indicated Andrew P. DeFilippis, Ty J. Gluckman, James Mudd, Catherine Campbell, Gregg Fonarow & Roger S. Blumenthal.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
European guidelines on the management of stable coronary artery disease Key points & new position for Ivabradine and Trimetazidine ESC 2013 Montalescot.
Clinical implications. Burden of coronary disease 56 millions deaths worldwide in millions deaths worldwide in % due to CV disease (~ 16.
Cardiovascular Disease in Women Module V: Prognosis and Treatment Outcomes.
VBWG CHARISMA Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance trial.
ACTIVE Clopidogrel plus Aspirin versus Aspirin in Patients Unsuitable for Warfarin.
D-1 Pravastatin-Aspirin Combination The Medical Need Thomas A. Pearson, M.D., Ph.D. Albert D. Kaiser Professor of Community & Preventive Medicine University.
ACUTE CORONARY SYNDROMES:
Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.
Aim To determine the effects of a Coversyl- based blood pressure lowering regimen on the risk of recurrent stroke among patients with a history of stroke.
Case Presentation A 62 year old woman asks whether she should take aspirin to prevent a heart attack and stroke, and if so how much? She is on hydrochlorothiazide.
The Relative Safety and Efficacy of Clopidogrel in Women and Men: A Sex-Specific Meta-Analysis Jeffrey S. Berger, Deepak L. Bhatt, Christopher P. Cannon,
Medical Prevention of Stroke November 17, 2000 Ash Singhal University of Toronto.
Vorapaxar for Secondary Prevention in Patients with Prior Myocardial Infarction Benjamin M. Scirica, MD, MPH On behalf of the TRA 2°P-TIMI 50 Steering.
* Based on post hoc analysis of individual outcome events (N=19,185). 1 Data on file, Sanofi Pharmaceuticals, Inc. 2 Gent M. Circulation. 1997; 96 (suppl):
Aggrenox Is it as good as the ads?. ESPS-2: European Stroke Prevention Study s Multicentre, randomized, double-blind, placebo-controlled trial s 6,602.
Naotsugu Oyama, MD, PhD, MBA A Trial of PLATelet inhibition and Patient Outcomes.
Clinical Overview Director, Stanford Stroke Center Stanford University Palo Alto, California Gregory W. Albers, MD.
Comparison of two cardiovascular risk assessment tools to determine appropriate use of aspirin as primary prevention for patients with type 2 diabetes.
Antithrombotic Trialists’ Collaboration An updated collaborative overview of randomised trials of antiplatelet therapy among high-risk patients.
A-1 Introduction Pravastatin-Aspirin 7asdf Fred T. Fiedorek, M.D. Vice President, Clinical Design & Evaluation, Metabolics Pharmaceutical Research Institute.
¨ 8 European countries, 48 centres Stent implantation Double-blind randomisation n = 1005 Clopidogrel 300mg od Aspirin 325mg od Clopidogrel 75mg od Aspirin.
Hypothesis: baseline risk status of the patients and proximity to a recent cardiovascular event influence the response to dual anti-platelet therapy. Patients.
ESPS-2: European Stroke Prevention Study s Multicentre, randomized, double-blind, placebo-controlled trial s 6,602 patients randomized within 3 months.
Case study - patient presenting with newly diagnosed NVAF with prior CAD Full Prescribing Information is provided at the end of this presentation EUAPI581k;
Long-Term Tolerability of Ticagrelor for Secondary Prevention: Insights from PEGASUS-TIMI 54 Trial Marc P. Bonaca, MD, MPH on behalf of the PEGASUS-TIMI.
Long-Term Tolerability of Ticagrelor for Secondary Prevention: Insights from PEGASUS-TIMI 54 Trial Marc P. Bonaca, MD, MPH on behalf of the PEGASUS-TIMI.
Bleeding After Initiation of Multiple Antithrombotic Drugs, Including Triple Therapy, in Atrial Fibrillation Patients Following Myocardial Infarction and.
The SYMPHONY Trial Reference Reddan DN, et al. Renal function, concomitant medication use and outcomes following acute coronary syndromes. Nephrol Dial.
Flow Diagram of the Trial Selection Process Jeffrey S. Berger et al, JAMA. 2006;295:
Angela Aziz Donnelly April 5, 2016
Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: ACC/AHA guidelines for percutaneous coronary intervention.
Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Making Sense of Statistics in Clinical Trial Reports:
1 R1 임준욱 Anticoagulant and Antiplatelet Therapy Use in 426 Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention and Stent Implantation.
Clinical Trial Commentary
Pain treatment How drugs work on pain.
Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Diabetes: A Meta-Analysis  Stavros Stavrakis, MD  The American Journal.
Blood Pressure and Age in Controlling Hypertension
Recent Breakthroughs in Cardiovascular Outcomes Trials in T2DM
Polypharmacy Anticoagulation: AF meets PCI
Effect of Aspirin Dose on Platelet Reactivity in Diabetic Patients Paul A. Gurbel, MD Director, Sinai Center for Thrombosis Research Sinai Hospital.
Clinical need for determination of vulnerable plaques
Women, Bleeding, and Coronary Intervention
2016 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation  Laurent Macle, MD, John Cairns, MD, Kori.
Focused 2012 Update of the Canadian Cardiovascular Society Atrial Fibrillation Guidelines: Recommendations for Stroke Prevention and Rate/Rhythm Control 
The following slides highlight a discussion and analysis of presentations in the Late-Breaking Clinical Trials session from the 55th Annual Scientific.
Antithrombotics and PAD: A New Paradigm in Practice
Webcast May 10th, 2004 Sponsored by
Figure 3 Ischaemic outcomes in the ST-segment elevation myocardial
George E. Kikano, MD, Marie T. Brown, MD  Mayo Clinic Proceedings 
Factor Xa Inhibitors in Coronary Artery Disease
2018 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation  Jason G. Andrade, MD, Atul Verma, MD,
Canadian Cardiovascular Society Atrial Fibrillation Guidelines 2010: Prevention of Stroke and Systemic Thromboembolism in Atrial Fibrillation and Flutter 
The Case for Routine CYP2C19 ( Plavix® ) Genetic Testing
The following slides highlight a report on a presentation at the American College of Cardiology 2004, Scientific Sessions, in New Orleans, Louisiana on.
Erratum Canadian Journal of Cardiology
Pamela E. Scott et al. JACC 2018;71:
Section C: Clinical trial update: Oral antiplatelet therapy
Cardiovascular Epidemiology and Epidemiological Modelling
Presentation transcript:

Aspirin Resistance: Significance, Detection and Clinical Management of This Real Phenomenon Webcast May 10 th, 2004 Sponsored by

Educational Objectives Define Aspirin Resistance, Incidence and Prevalence in the Population Describe the Mechanisms for Aspirin Resistance and Reduced Platelet Inhibition Understand the Importance of Aspirin Resistance Testing, Methods of Detection Understand Clinical Implication and Clinical Decisions in Aspirin Resistant Patients

Faculty Steven Steinhubl, M.D. Director of Cardiovascular Research and Education Associate Professor of Medicine University of Kentucky, Lexington, Kentucky Daniel I. Simon, M.D. Associate Professor of Medicine Harvard Medical School Associate Director, Interventional Cardiology Brigham and Women’s Hospital, Boston, Massachusetts Christopher Cannon, M.D. Associate Professor Of Medicine, Harvard Medical School Senior Investigator, TIMI Study Group Associate Physician, Brigham and Women’s Hospital Boston, Massachusetts

Aspirin in Cardiovascular Disease Christopher Cannon, M.D. Brigham and Women’s Hospital Boston, MA

Vascular Disease in the U.S. 1.American Heart Association Heart Disease and Stroke Statistics. 2.Brown et al. Amer. Stroke Assoc. 25th Int. Stroke Conference National Stroke Association Press Release. April 25, Hirsch AT et al. JAMA. 2001;286:11: TIA = transient ischemic attack. ACS = acute coronary syndrome. PAD = peripheral arterial disease. Annual Incidence (Millions) Prevalence (Millions) Stroke TIA ACS1.7 1 *14.2 1† PAD  8–12 4

Number of Patients (Millions) ACC/AHA Guidelines 2001, NHLBI Chartbook 2000 and Foot et al (JACC 2000) U.S. Heart Disease Doubles in the Next Half Century

Estimated Direct and Indirect Costs of Cardiovascular Diseases and Stroke $214 $111.8 $49.4 $47.2 $23.2 $ $50 $100 $150 $200 $250 $300 $350 Heart disease Coronary Heart disease Stroke Hypertensive disease Congestive heart failure Total CVD 3 Billions estimates (USA) 2 American Heart Association Heart and Stroke Statistical Update CVD = cardiovascular disease

Aspirin Usage In the US Percentage of Use % 20% 30% 40% Heart Disease ArthritisHeadacheBody Ache Other 26,000,000 Americans receive chronic aspirin therapy for cardioprotection.

Antithrombotic Trialists’ Collaboration (ATC): Efficacy of Antiplatelet Therapy on Vascular Events Antithrombotic Trialists’ Collaboration. BMJ 2002; 324: 71–86. *Vascular events = myocardial infarction, stroke or vascular death Category% Odds Reduction Acute myocardial infarction Acute stroke Prior myocardial infarction Prior stroke/transient ischemic attack Other high risk Coronary artery disease (e.g. unstable angina, heart failure) Peripheral arterial disease (e.g. intermittent claudication) High risk of embolism (e.g. atrial fibrillation) Other (e.g. diabetes mellitus) All trials Control better Antiplatelet better

Plac.ASA Acute Myocardial Infarction RISC Group. Lancet 1990;336: Roux etal.JACC 1992;19: ISIS-2.Lancet 1988;2: ISIS-2.Lancet 1988;2: Aspirin in Acute Coronary Syndromes

Primary Prevention Stable Angina PHS.NEJM 1989;321: Ridker etal.AJC 1991;114: Theroux, etal.NEJM 1988;319: Cairns, etal.NEJM 1985;313:

Indirect Comparisons of ASA Doses on Vascular Events in High-Risk Patients *Odds reduction. Treatment effect P< ASA, acetylsalicylic acid. Adapted with permission from BMJ Publishing Group. Antithrombotic Trialists’ Collaboration. BMJ. 2002;324: mg mg mg12 32 <75 mg 3 13 Any aspirin65 23 Antiplatelet BetterAntiplatelet Worse Aspirin DoseNo. of Trials (%) Odds Ratio 0 OR*

Clopidogrel + ASA (N=6259) ASA (N=6303) ASA Dose: <100 mg (N=1927) 1.9% 3.0% mg (N=7428) 2.8% 3.4% >200 mg (N=2301) 3.7% 4.9% Major Bleeding at 1 year by ASA Dose CURE P-Value Peters RJG, et al. Circulation 2003;108:

BRAVO: Bleeding By ASA dose Topol EJ, et al. Circulation. 2003;108: Outcomes by Aspirin Dose in Placebo Study Drug Patients Low Dose, mg/d (n=2410) Higher Dose, mg/d (n=2179) Primary end point Death, MI, stroke Death MI Stroke Internal bleeding Any bleeding Transfusion1.02.0

Aspirin in Cardiovascular Disease Aspirin is proven to reduce death, MI, stroke in patients with all types of cardiovascular disease Inexpensive, widely available Dosing now focused on low-dose (75-81 mg) for optimal efficacy / safety balance However… Does one dose fit all? Is there Aspirin resistance? Are their clinical consequences of Aspirin resistance?